Last reviewed 2026-05-14 · How we verify

every week IVMP therapy

Medical University of Warsaw · FDA-approved active Small molecule

every week IVMP therapy is a Corticosteroid (glucocorticoid) Small molecule drug developed by Medical University of Warsaw. It is currently FDA-approved for Multiple sclerosis (relapse treatment), Autoimmune inflammatory conditions, Severe inflammatory or autoimmune disorders.

Intravenous methylprednisolone (IVMP) is a corticosteroid that suppresses immune and inflammatory responses by inhibiting cytokine production and immune cell activation.

Intravenous methylprednisolone (IVMP) is a corticosteroid that suppresses immune and inflammatory responses by inhibiting cytokine production and immune cell activation. Used for Multiple sclerosis (relapse treatment), Autoimmune inflammatory conditions, Severe inflammatory or autoimmune disorders.

At a glance

Generic name	every week IVMP therapy
Sponsor	Medical University of Warsaw
Drug class	Corticosteroid (glucocorticoid)
Target	Glucocorticoid receptor
Modality	Small molecule
Therapeutic area	Immunology / Rheumatology / Neurology
Phase	FDA-approved

Mechanism of action

IVMP is a synthetic glucocorticoid administered intravenously, typically in high doses on a weekly schedule. It works by binding to glucocorticoid receptors in immune cells, suppressing T-cell and B-cell function, reducing pro-inflammatory cytokine production, and stabilizing cell membranes to reduce inflammation. This broad immunosuppressive effect makes it useful in autoimmune and inflammatory conditions.

Approved indications

Multiple sclerosis (relapse treatment)
Autoimmune inflammatory conditions
Severe inflammatory or autoimmune disorders

Common side effects

Hyperglycemia
Hypertension
Insomnia
Mood changes
Immunosuppression / increased infection risk
Osteoporosis (with chronic use)

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

every week IVMP therapy CI brief — competitive landscape report
every week IVMP therapy updates RSS · CI watch RSS
Medical University of Warsaw portfolio CI

Frequently asked questions about every week IVMP therapy

What is every week IVMP therapy?

every week IVMP therapy is a Corticosteroid (glucocorticoid) drug developed by Medical University of Warsaw, indicated for Multiple sclerosis (relapse treatment), Autoimmune inflammatory conditions, Severe inflammatory or autoimmune disorders.

How does every week IVMP therapy work?

Intravenous methylprednisolone (IVMP) is a corticosteroid that suppresses immune and inflammatory responses by inhibiting cytokine production and immune cell activation.

What is every week IVMP therapy used for?

every week IVMP therapy is indicated for Multiple sclerosis (relapse treatment), Autoimmune inflammatory conditions, Severe inflammatory or autoimmune disorders.

Who makes every week IVMP therapy?

every week IVMP therapy is developed and marketed by Medical University of Warsaw (see full Medical University of Warsaw pipeline at /company/medical-university-of-warsaw).

What drug class is every week IVMP therapy in?

every week IVMP therapy belongs to the Corticosteroid (glucocorticoid) class. See all Corticosteroid (glucocorticoid) drugs at /class/corticosteroid-glucocorticoid.

What development phase is every week IVMP therapy in?

every week IVMP therapy is FDA-approved (marketed).

What are the side effects of every week IVMP therapy?

Common side effects of every week IVMP therapy include Hyperglycemia, Hypertension, Insomnia, Mood changes, Immunosuppression / increased infection risk, Osteoporosis (with chronic use).

What does every week IVMP therapy target?

every week IVMP therapy targets Glucocorticoid receptor and is a Corticosteroid (glucocorticoid).

Drug class: All Corticosteroid (glucocorticoid) drugs
Target: All drugs targeting Glucocorticoid receptor
Manufacturer: Medical University of Warsaw — full pipeline
Therapeutic area: All drugs in Immunology / Rheumatology / Neurology
Indication: Drugs for Multiple sclerosis (relapse treatment)
Indication: Drugs for Autoimmune inflammatory conditions
Indication: Drugs for Severe inflammatory or autoimmune disorders

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing